Extramural Research Programs in the Neurosciences and Neurological Disorders

Active

Assistance listing
93.853
Agency
Grant awards
43,866 $45,545,088,435 in federal obligations

Program facts

Assistance types
  • Project Grant
  • Cooperative Agreement
  • Block Grant
Treasury account
  • 75-0886-0-1-552
More information

Program details come from SAM.gov Assistance Listings. Updated . Grant award figures come from USAspending.gov.

About this program

The National Institute of Neurological Disorders and Stroke (NINDS) within the Department of Health and Human Services National Institutes of Health funds extramural research in neuroscience and neurological disorders under Assistance Listing 93.853, with the most recent award dated February 26, 2027, at $50,114.

This program supports basic and translational neuroscience research investigating fundamental brain and nervous system structure and function, disease mechanisms in neurological disorders, and therapeutic development. The portfolio includes clinical trials evaluating novel therapeutics, fellowship training grants, and Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) initiatives. Peer review occurs through technical panels composed of scientific experts and the National Advisory Neurological Disorders and Stroke Council, with funded projects competing on merit basis.

The portfolio is overwhelmingly dominated by Project Grants, which comprise 94 percent of awards (41,121 awards), with smaller shares of Block Grants (4 percent) and Cooperative Agreements (2 percent). NINDS itself manages the vast majority of funding: the National Institute of Neurological Disorders and Stroke directly administered 13,611 awards totaling $31.25 billion in federal dollars obligated, while parent-level NIHNIH administered an additional 28,994 awards worth $12.7 billion, establishing NINDS dominance across the portfolio. Combined federal and non-federal dollars obligated reached $47.44 billion, indicating substantial institutional and recipient cost-sharing. Typical Project Grant awards cluster in the $35,000 to $85,000 range for recent postdoctoral fellowship and early-career awards, with some larger U24 and RM1 mechanism awards reaching $150,000 to $227,000.

Recent awards reflect the program's scope: projects investigating spinal cord injury and locomotor recovery, glioblastoma tumor microenvironment mechanisms, multiple sclerosis cognitive dysfunction, epilepsy sudden unexpected death mechanisms, motor cortex reaching control, vestibular balance circuits, epilepsy surgery candidate identification using machine learning, cerebrospinal fluid dynamics, meningeal fibroblast development, cerebellar motor planning, synaptic zinc signaling, stress-induced migraine mechanisms, and gene replacement therapy for lysosomal storage disease. The portfolio spans basic mechanistic studies through clinical neurobiology to applied therapeutics and device development.

Grant opportunities posted in recent months are predominantly forecasts of future solicitations, not currently open competitions. These include cooperative agreements for clinical trial networks (NeuroNEXT, StrokeNet, SIREN, Undiagnosed Diseases Network), BRAIN Initiative technology dissemination and clinical device studies, ALS expanded access protocols, and targeted research programs in Alzheimer's disease mechanisms, pain network genomics, and medical device optimization. The Academic Career Excellence (K32) award for postdoctoral scholars is currently open with a due date of July 12, 2029.

Objective and description

Objective

(1) To support extramural research funded by the National Institute of Neurological Disorders and Stroke (NINDS) including: basic research that explores the fundamental structure and function of the brain and the nervous system; research to understan

Description

The mission of NINDS is to seek fundamental knowledge about the brain and nervous system and to use that knowledge to reduce the burden of neurological disease for all people.

Eligibility

Applicant eligibility

Research Grants: Any public, private, nonprofit, or for-profit institution is eligible to apply. For-profit institutions are not eligible for Institutional National Research Service Awards but are eligible for Individual NRSAs. All proposals are reviewed for scientific merit, for evaluation of the qualifications of the investigators, for adequacy of the research environment, and for significance of the problem. Approved proposals compete for available funds. All Career Development Program awardees, with the exception of awardees of the Pathway to Independence Award (K99/R00), must be citizens or have been admitted to the United States for permanent residence. Candidates must be nominated for the program by a nonfederal public or private nonprofit institution located in the United States, its possessions or territories. To be eligible, postdoctoral NRSA trainees or fellows must have a professional or scientific degree (M.D., Ph.D., D.D.S., D.O., D.V.M., Sc.D., D. Eng., or equivalent domestic or foreign degree). SBIR grants can be awarded only to domestic small businesses (entities that are independently owned and operated for profit, are not dominant in the field in which research is proposed, and have no more than 500 employees). Primary employment (more than one-half time) of the principal investigator must be with the small business at the time of award and during the conduct of the proposed project. In both Phase I and Phase II, the entire research must be performed in the United States. To be eligible for funding, a grant application must be approved for scientific merit and program relevance by a scientific review group and a national advisory council. STTR grants can be awarded only to domestic small business concerns (entities that are independently owned and operated for profit, are not dominant in the field in which research is proposed and have no more than 500 employees) which "partner" with a research institution in cooperative research and development. At least 40 percent of the project is to be performed by the small business concern and at least 30 percent by the research institution. In both Phase I and Phase II, the research must be performed in the U.S. and its possessions. To be eligible for funding, a grant application must be approved for scientific merit and program relevance by a scientific review group and a national advisory council.

Beneficiary eligibility

Health professionals, graduate students, health professional students, scientists, and researchers.

Uses of assistance

Research grants may be used to provide salaries, equipment, supplies, travel and other expenses for research. The grantee institution is obliged to expend grant funds prudently for the purposes stated in the application and award document. National Research Service Awards (NRSAs) are made directly to individuals for research training in specified biomedical shortage areas, or to institutions, to enable them to make NRSAs to individuals selected by them. Each individual who receives a NRSA may be obligated upon termination of the award to comply with service and payback provisions. Career Development Awards such as the Independent Scientist Awards (K02) provide support for newly independent scientists with health-related degrees who can demonstrate the need for a period of intensive research focus as a means of enhancing their research careers and facilitating their ability to obtain major NIH research awards. Mentored Clinical Research Scientist Development Awards (K08) provide support for clinically trained health professionals who need an additional period of sponsored research experience as a way to gain expertise in a research area new to the candidate or in an area that would demonstrably enhance the candidate's scientific career. The K01 and K22 Mentored Research Scientist Development Awards are used to promote diversity in neuroscience research and support an intensive supervised research career development experience for underrepresented, disabled or disadvantaged career neuroscientists. The Mentored Patient-Oriented Research Career Development Award (K23) provide support for a period of supervised study and research for clinically trained professionals who have the potential to develop into productive clinical investigators. SBIR and STTR Phase I grants (of approximately 6-months to 2 years in duration) are to establish the technical merit and feasibility of a proposed research effort that may lead to a commercial product or process. Phase II grants (of approximately 1 to 3 years in duration) are for the continuation of the research efforts initiated in Phase I that are likely to result in commercial products or processes. Phase II funding is based on results of research initiated in Phase I, scientific and technical merit, and commercial potential of Phase II application. Grant funds may be expended only for the purpose stated in the application and award document. The NINDS participates in the NIH SBIR/STTR "fast track" and Phase IIB initiatives.

Length and time phasing of assistance

Research grant awards are made for a 12-month period with recommendation of up to 4 years of additional support, with limited exceptions for longer duration awards. Career Program awards provide support for 3 to 5 years. Training Program awards are usually for a 12-month period with recommendation of additional support of up to a total of 5 years for predoctoral training and no more than 3 years for postdoctoral training. SBIR: Normally, Phase I awards are for 6 months; normally, Phase II awards are for 2 years. STTR: Normally, Phase I awards are for 1 year; normally, Phase II awards are for 2 years. Method of awarding/releasing assistance: quarterly.

How to apply

Preapplication coordination

Research grant applications that request $500,000 or more in direct costs in any yearly budget period will not be accepted unless the NINDS has agreed to accept the application prior to submission (see http://grants.nih.gov/grants/guide/notice-files/NOT-OD-02-004.html).

Criteria for selecting proposals

The major elements in evaluating proposals include assessments of: (1) the scientific merit and general significance of the proposed study and its objectives; (2) the technical adequacy of the experimental design and approach; (3) the competency of the proposed investigator or group to successfully pursue the project; (4) the adequacy of the available and proposed facilities and resources; (5) the necessity of the budget components requested in relation to the proposed project; and (6) the relevance and importance to announced program objectives. The following criteria will be used in considering the scientific and technical merit of SBIR/STTR Phase I grant applications: (1) the soundness and technical merit of the proposed approach; (2) the qualifications of the proposed principal investigator, supporting staff, and consultants; (3) the technological innovation of the proposed research; (4) the potential of the proposed research for commercial application; (5) the appropriateness of the budget requested; (6) the adequacy and suitability of the facilities and research environment; and (7) where applicable, the adequacy of assurances detailing the proposed means for (a) safeguarding human or animal subjects, and/or (b) protecting against or minimizing any adverse effect on the environment. Phase II grant applications will be reviewed based upon the following criteria: (1) the degree to which the Phase I objectives were met and feasibility demonstrated; (2) the scientific and technical merit of the proposed approach for achieving the Phase II objectives; (3) the qualifications of the proposed principal investigator, supporting staff, and consultants; (4) the technological innovation, originality, or societal importance of the proposed research; (5) the potential of the proposed research for commercial application; (6) the reasonableness of the budget requested for the work proposed; (7) the adequacy and suitability of the facilities and research environment; and 8) where applicable, the adequacy of assurances detailing the proposed means for (a) safeguarding human or animal subjects, and/or (b) protecting against or minimizing any adverse effect on the environment.

Award procedure

Research Grant, Training, Fellowship and SBIR/STTR applications are reviewed initially by technical panels, composed of scientific authorities, and by the National Advisory Neurological Disorders and Stroke Council composed of 18 leaders in medical science, education, and public affairs. Approved applications will compete on a merit basis for available funds. Formal award notices are transmitted to the grantee or awardee.

Time to approval or disapproval

Research grants: Approximately 6 to 9 months. Career program: From 7 to 8 months. SBIR/STTR applications: Approximately 6 to 9 months. Institutional Training Grants: From 6 to 12 months.

Renewals

By application and review in same manner as new applications. A P.I. should consult the specific NOFO to determine if a particular grant is renewable.

Appeals

A principal investigator (P.I.) may question the substantive or procedural aspects of the review of his/her application by communicating with the staff of the Institute, and subsequently, the P.I. and applicant institution may appeal to the NINDS appeals officer. A description of the NIH Peer Review Appeal procedures is available on the NIH home page http://grants.nih.gov/grants/guide/notice-files/NOT-OD-11-064.html.

Grant opportunities

Opportunity Status Posted Applications due
Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required) RFA-NS-28-009 Forecasted —
Research to Improve Rigor, Replicability, and Reproducibility in Biomedical and Behavioral Sciences PAR-28-061 Forecasted —
Network for Excellence in Neuroscience Clinical Trials (NeuroNEXT) Infrastructure - Clinical Research Sites (U24 Clinical Trial Not Allowed) RFA-NS-28-007 Forecasted —
NIH Stroke Clinical Trials Network (StrokeNet) Infrastructure - National Coordinating Center (NCC) and National Data Management Center (NDMC) RFA-NS-28-003 Forecasted —
Undiagnosed Diseases Network (UDN) Clinical and Data Coordinating Center PAR-27-135 Forecasted —
Undiagnosed Diseases Network (UDN) Clinical Networks of Diagnostic Excellence PAR-27-137 Forecasted —
Limited Competition: BRAIN Initiative: Promoting Health for All Through BRAIN Technology Partnerships RFA-NS-28-005 Forecasted —
Network for Excellence in Neuroscience Clinical Trials (NeuroNEXT) Infrastructure - Clinical Coordinating Center (CCC) & Data Coordinating Center (DCC) RFA-NS-28-002 Forecasted —
BRAIN Initiative: Clinical Studies to Advance Next-Generation Devices for Recording and Modulation in the Human Central Nervous System RFA-NS-28-006 Forecasted —
NIH Stroke Clinical Trials Network (StrokeNet) Infrastructure - Regional Coordinating Stroke Centers (RCCs) RFA-NS-28-008 Forecasted —
Undiagnosed Diseases Network (UDN) Diagnostic Research Innovation Center PAR-27-136 Forecasted —
Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN) Infrastructure - Clinical Enrollment Hubs RFA-NS-28-004 Forecasted —
Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN) Infrastructure - Clinical Coordinating Center (CCC) and Data Coordinating Center (DCC) RFA-NS-28-001 Forecasted —
Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development PAR-28-043 Forecasted —
Academic Career Excellence (ACE) Award (K32 Independent Clinical Trial Not Allowed) PAR-27-062 Open
Development of Candidate Medical Countermeasures (MCMs) and Technologies Against Radiological/Nuclear or Chemical Threats (U01 Clinical Trial Not Allowed) RFA-AI-27-014 Open
HEAL Initiative: Optimization of Therapeutic Medical Devices through Team Science Mechanistic Research (RM1) RFA-NS-26-028 Forecasted —
Clinical Trials and Ancillary Studies Conducted within NIH-Funded Clinical Trial Research Networks (UG3/UH3 - Clinical Trial Required) PAR-27-007 Forecasted —
Exposomic Contributions to ADRD Pathology and Resilience RFA-NS-26-031 Past —
Centers without Walls for mechanisms of neurodegeneration in Alzheimer's disease-related dementias (ADRD) RFA-NS-26-032 Past —
Functional Target Validation for Alzheimer's Disease-Related Dementias RFA-NS-26-034 Forecasted —
Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Therapeutic Agent Characterization and Preclinical Efficacy Studies PAR-26-057 Past —
Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Assay Development and Therapeutic Agent Identification PAR-26-058 Past —
HEAL Initiative: Program to Reveal and Evaluate Cells-to-gene Information that Specify Intricacies, Origins and the Nature of (PRECISION) Human Pain Network RFA-NS-26-013 Past —
Collaborative Program Grant for Interdisciplinary Teams (RM1 Clinical Trial Optional) PAR-27-003 Open
NLM Institutional Grants for Research Training in Biomedical Informatics, Data Science, and AI (T15 Independent Clinical Trial Not Allowed) RFA-LM-28-001 Open
HEAL Initiative: Whole Joint Health Program (R61/R33 Clinical Trial Required) PAR-27-045 Open
Genomic and Biologic Therapies for ADRD (U01 Clinical Trial Optional) RFA-NS-26-030 Forecasted —
Institutional Mentored Career Development Award (Parent K12) (Clinical Trials Not Allowed) PA-27-030 Open
Lasker Clinical Research Scholar's Program (Si2/R00 Clinical Trial Optional) PAR-27-076 Open
NIH Collaborative International Research Project (Parent PF5 Clinical Trial Optional) PA-26-002 Open
NIH Research Education Program - Research Experiences (Parent R25 - Clinical Trial Not Allowed) PA-27-036 Open
NIH Research Educational Program - Mentoring Activities & Networks (Parent R25/UE5 - Clinical Trial Not Allowed) PA-27-035 Open
Palliative Care Research Across the Lifespan: Leveraging the Palliative Care Consortium (R01 Clinical Trial Optional) PAR-27-090 Open
Investigate Novel Therapeutic Interventions and Testing Strategies for Neurological Disorders Including to Treat, Modify and Prevent the Development of Epilepsy (U24 Clinical Trial Not Allowed) RFA-NS-26-002 Past —
NIH Brain Development Cohorts (NBDC) and Population Assessment of Tobacco and Health (PATH) Study Biospecimen Access (X01 Clinical Trial Not Allowed) PAR-27-051 Open
Bioengineering Research Grants (BRG) (R01 Clinical Trial Optional) PAR-27-072 Open
Single Source: Post-Stroke Vascular Contributions to Cognitive Impairment and Dementia (VCID) in the United States (U19 - Clinical Trial Not Allowed) RFA-NS-27-011 Closed
Stroke Preclinical Assessment Network (SPAN) to Support Translational Studies for Acute Cerebroprotection - Network Sites and Coordinating Center (U01- CT Not Allowed) RFA-NS-26-012 Past —
Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required) RFA-NS-26-001 Open
BRAIN Initiative: Integrative Team-Research BRAIN Circuits Program - iBCP (RM1 Clinical Trial Not Allowed) RFA-NS-27-002 Open
NINDS Efficacy and Exploratory Clinical Trials (UG3/UH3 - Clinical Trial Required) PAR-27-065 Open
HEAL Initiative: Pain Management Effectiveness Research Network: Clinical Trial Planning and Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required) RFA-NS-25-031 Past —
BRAIN Initiative: Research Opportunities Using Invasive Neural Recording and Stimulating Technologies in the Human Brain (R01 Clinical Trial Not Allowed) RFA-NS-28-010 Open
Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional) PA-26-001 Open
Limited Competition: Instrumentation Grant Program for Resource-Limited Institutions (S10 - Clinical Trial Not Allowed) PAR-27-067 Open
HEAL Initiative: Integrative Management of chronic Pain and OUD for Whole Recovery (IMPOWR) - Building Engagement, Assistance, Capacity, Outreach, and Networks (BEACON) Center (U2C Clinical Trial Not Allowed) RFA-DA-28-012 Open
Smart Health and Biomedical Research in the Era of Artificial Intelligence and Advanced Data Science 25-542 Closed
HEAL Initiative: Integrative Management of Chronic Pain and OUD for Whole Recovery (IMPOWR): Research Centers (RM1 Clinical Trial Required) RFA-DA-28-011 Open
NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional) PA-27-100 Open
Show 40 more

Latest 50 listed here. See the rest on GovTribe.

Grant awards

Latest 10 of 43,866 listed here. See the rest on GovTribe.

Top recipients by federal obligations

Rank Recipient Federal obligations Share
1 The General Hospital Corporation $1,309,596,942 3%
2 The Regents Of The University Of California. San Francisco $1,204,076,115 3%
3 The Johns Hopkins University $1,055,413,992 2%
4 The Trustees Of Columbia University In The City Of New York $984,237,455 2%
5 The Leland Stanford Junior University $861,794,155 2%
6 Regents Of The University Of Michigan $860,692,721 2%
7 The Washington University $858,642,954 2%
8 Yale Univ $810,273,687 2%
9 The Trustees Of The University Of Pennsylvania $805,579,030 2%
10 Northwestern University $781,053,152 2%

10 of 1,425 recipients listed here. See the rest on GovTribe.

Federal obligations by fiscal year

Fiscal year Federal obligations
FY2026 $2,075,873,698
FY2025 $2,823,147,077
FY2024 $3,778,693,816
FY2023 $4,554,699,056
FY2022 $3,782,742,523
FY2021 $3,834,253,959
FY2020 $2,125,395,195
FY2019 $1,934,070,820
FY2018 $1,722,668,649
FY2017 $1,482,889,028
FY2016 $1,423,053,419
FY2015 $1,325,559,706
FY2014 $1,305,997,550
FY2013 $1,262,917,242
FY2012 $1,336,617,486
FY2011 $1,327,853,551
FY2010 $1,354,168,040
FY2009 $1,320,826,858
FY2008 $673,393,217
FY2007 $922,324,245
FY2006 $1,151,418,991
FY2005 $1,230,766,604
FY2004 $1,203,244,842
FY2003 $1,172,241,672
FY2002 $1,151,208,668
FY2001 $318,356,878
Show all 26

Quick answers

What is Assistance Listing 93.853?

Assistance Listing 93.853 is Extramural Research Programs in the Neurosciences and Neurological Disorders, a federal grant program run by National Institutes of Health (Department of Health and Human Services).

What is the CFDA number for Extramural Research Programs in the Neurosciences and Neurological Disorders?

Its CFDA number is 93.853: Assistance Listing numbers were called CFDA numbers before 2018.

How much funding has Assistance Listing 93.853 awarded?

43,866 grant awards under 93.853 have obligated $45,545,088,435 in federal funds to 1,425 recipients.

Who receives the most funding from 93.853?

The recipients obligated the most under Extramural Research Programs in the Neurosciences and Neurological Disorders are The General Hospital Corporation ($1,309,596,942), The Regents Of The University Of California. San Francisco ($1,204,076,115) and The Johns Hopkins University ($1,055,413,992).

How much did 93.853 obligate in fiscal year 2025?

Grants under 93.853 obligated $2,823,147,077 in federal funds in fiscal year 2025.

Are there open grant opportunities under 93.853?

40 of the latest 50 opportunities under 93.853 are open or forecasted. The latest, Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required), was posted on September 23, 2026.

On GovTribe

See this program's full record

  • Every grant award and opportunity under it
  • Funding by recipient, agency and assistance type
  • Alerts for new opportunities
  • Ask GovTribe AI about this program